Recent News

• 04.11.2025 - argenx Announces Annual General Meeting of Shareholders on May 27, 2025
• 04.11.2025 - argenx Announces Annual General Meeting of Shareholders on May 27, 2025
• 04.10.2025 - argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
• 04.10.2025 - argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
• 04.08.2025 - argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
• 04.08.2025 - argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
• 03.07.2025 - argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
• 03.07.2025 - argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
• 02.27.2025 - argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
• 02.27.2025 - argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

Recent Filings

• 04.11.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.11.2025 - EX-99.1 EX-99.1
• 04.08.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.08.2025 - EX-99.1 EX-99.1
• 03.20.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.20.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 03.20.2025 - EX-99.1 EX-99.1
• 03.07.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.07.2025 - EX-99.1 EX-99.1
• 02.27.2025 - EX-99.1 EX-99.1